Related Experiment Videos
Paternal leucocyte immunotherapy for recurrent pregnancy loss
1Sanjay Gandhi Postgraduate Institute of Medical Sciences, Uttar Pradesh, India.
The National Medical Journal of India
|May 1, 1995
Summary
Immunotherapy may prevent recurrent pregnancy loss by enhancing the maternal immune response to foetal antigens. However, its precise mechanism and effectiveness require further investigation due to variable clinical trial outcomes.
Area of Science:
- Reproductive Immunology
- Maternal-Foetal Medicine
Background:
- Recurrent pregnancy loss is linked to the maternal immune system's failure to recognize foetal alloantigens.
- Immunotherapy using leucocyte immunization is a potential strategy to improve pregnancy outcomes.
Purpose of the Study:
- To review the current state of immunotherapy for recurrent foetal loss.
- To discuss the potential mechanisms of action for immunotherapy in preventing recurrent pregnancy failure.
Main Methods:
- Review of existing literature on immunotherapy for recurrent spontaneous abortion.
- Analysis of clinical trial data and success rates.
- Discussion of immunological mechanisms.
Main Results:
- Immunotherapy has shown variable success rates in clinical trials, with reported pregnancy rates up to 70%.
- High success rates in control groups complicate the interpretation of immunotherapy's efficacy.
- Variability in results may stem from small sample sizes, population heterogeneity, and placebo effects.
Conclusions:
- The exact mechanism by which leucocyte immunization prevents recurrent foetal loss remains unclear.
- Further research is needed to elucidate the mechanisms and optimize immunotherapy protocols for recurrent pregnancy failure.